| Rank |
Status |
Study |
| 1 |
Recruiting
|
Effect of Body Mass on Acyclovir Pharmacokinetics
| Conditions: |
Hematological Malignancy; Pharmacokinetics of Acyclovir |
| Intervention: |
|
| Outcome Measures: |
Systemic clearance of Acyclovir in obese and non-obese patients; Alpha and beta half-life of Acyclovir in obese and non-obese patients; Maximum concentration (Cmax) of Acyclovir in obese and non-obese patients; Time to maximum concentration (Tmax) of Acyclovir in obese and non-obese patients; Volume of distribution (Vd and Vdss) of Acyclovir in obese and non-obese patients; Time that concentration is above IC50 for varicella and herpes viruses 4,5,6,7 for Acyclovir in obese and non-obese patients |
|
| 2 |
Recruiting
|
Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease
| Condition: |
Meniere's Disease |
| Interventions: |
Drug: Acyclovir; Drug: Placebo |
| Outcome Measures: |
Vertigo; Hearing Loss; Aural Fullness; Tinnitus |
|
| 3 |
Recruiting
|
Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster
| Condition: |
Herpes Zoster |
| Interventions: |
Drug: Famciclovir; Drug: Aciclovir |
| Outcome Measures: |
For efficacy evaluation, a visual analogue scale (VAS) will be used to detect the improvement of symptoms; Safety will be evaluated by the adverse events occurrences |
|
| 4 |
Recruiting
|
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
| Condition: |
GENITAL HERPES |
| Interventions: |
Drug: Famciclovir; Drug: Aciclovir |
| Outcome Measures: |
Efficacy will be evaluated by the proportion of subjects with non herpes manifestation; Safety will be evaluated by the Adverse events occurence |
|
| 5 |
Recruiting
|
PTH - Preemptive Treatment for Herpesviridae
| Condition: |
Viral Pneumonia |
| Interventions: |
Drug: Aciclovir; Drug: Ganciclovir; Drug: Placebo |
| Outcome Measures: |
Ventilator-free days at Day 60; Day 60 mortality; ICU mortality; Hospital mortality; Duration of mechanical ventilation in survivors; Duration of ICU stay; Duration of hospital stay; Incidence of ventilator-associated pneumonia; Incidence of bacteremia; SOFA score; Acute renal failure related to aciclovir or its placebo; Leucopenia related to ganciclovir or its placebo; Time to oropharyngeal negativation of HSV PCR; Time to blood negativation of CMV PCR; Incidence of herpetic bronchopneumonia; Incidence of active CMV infection |
|
| 6 |
Not yet recruiting
|
A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC
| Condition: |
Articular Cartilage Defect |
| Interventions: |
Procedure: ACIC; Procedure: MCIC; Device: implant with a collagen + fibrin gel mixture |
| Outcome Measures: |
Clinical outcome; Radiological outcome |
|
| 7 |
Recruiting
|
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC)
| Condition: |
Obesity |
| Intervention: |
Other: Salivary Cortisol |
| Outcome Measures: |
Number of patients with positive salivary cortisol dosage among patients with positive serum cortisol dosage; Number of patients with negative salivary cortisol dosage among patients with negative serum cortisol dosage; Comparing the results of salivary cortisol dosage and serum cortisol dosage; Comparing the results of the two salivary samples; Number of patients with metabolic complications of obesity among patients with ACIC; Number of patients with severe type 2 diabetes among patients with ACIC |
|
| 8 |
Not yet recruiting
|
Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster
| Condition: |
Herpes Zoster |
| Interventions: |
Drug: Foscarnet Sodium; Drug: Acyclovir |
| Outcome Measures: |
Effective rate; Incidence of Postherpetic neuralgia; number of participants with adverse event and serious adverse event |
|
| 9 |
Recruiting
|
Cytomegalovirus Control in Critical Care
| Condition: |
Critical Illness |
| Interventions: |
Drug: Valaciclovir/Aciclovir; Drug: Valganciclovir/Ganciclovir |
| Outcome Measures: |
Time to reactivation of cytomegalovirus (CMV) polymerase chain reaction (PCR) (defined as above the lower limit of sample assay).; Time to reactivation above the lower limit of assay detection of CMV PCR in urine, throat swab and non-directed bronchiolar lavage (NDBL). NDBL whilst trachea is intubated only.; Time to >1000 CMV copies in blood, urine, throat swab and NDBL (NDBL whilst intubated); Time to >10000 CMV copies in blood, urine, throat swab and NDBL (NDBL whilst intubated); CMV PCR in blood, urine, throat swab and NDBL (NDBL whilst intubated); Markers of inflammation; Clinical Outcomes; Number of Serious Adverse events; Time to neutropenia (count <1.0x10-9/L); Time to thrombocytopenia (platelet <50x10-9/L); Use of G-CSF or termination of study drug; Number of platelet transfusions received; Time to renal insufficiency (CrCl <60ml/min, <30ml/min, need for renal support) |
|
| 10 |
Unknown †
|
Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System
| Condition: |
Herpes Simplex |
| Intervention: |
Drug: Acyclovir |
| Outcome Measure: |
|
|
| 11 |
Unknown †
|
Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
| Condition: |
Reccurent Herpes Labialis |
| Interventions: |
Drug: Acyclovir 5%; Drug: Docosanol 10%; Device: Superlysine gel |
| Outcome Measure: |
Reducing healing process and duration of cold sores using superlysin gel |
|
| 12 |
Recruiting
|
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
| Condition: |
Non-Small Cell Lung Cancer |
| Interventions: |
Drug: Bortezomib; Drug: Acyclovir |
| Outcome Measures: |
efficacy of single-agent subcutaneous bortezomib; Efficacy; Toxicity |
|
| 13 |
Recruiting
|
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
| Condition: |
Metastatic Castration-resistant Prostate Cancer |
| Interventions: |
Drug: Carfilzomib; Drug: Dexamethasone; Drug: Acyclovir |
| Outcome Measures: |
Progression-free survival (PFS); Prostate-Specific Antigen (PSA) changes; Circulating Tumor Cell (CTC) enumeration; Baseline whole blood 20S proteasome level; Measurable disease response rate; Pain response; Overall survival; Assessment of toxicities |
|
| 14 |
Not yet recruiting
|
A Multiple Ascending Dose-Finding Pharmacokinetic and Pharmacodynamic Study of a Novel Antiviral Drug in Infants With Neonatal Herpes Simplex Virus (HSV)
| Condition: |
Herpes Simplex Virus |
| Interventions: |
Drug: Novel Antiviral Drug; Drug: Placebo |
| Outcome Measures: |
Plasma pharmacokinetic parameters for a Novel Antiviral Drug, including AUC24, maximum serum concentration (Cmax), half-life (T1/2), CL/F, and time to maximum concentration (Tmax); Clearance of HSV DNA from CSF by Day 4 of antiviral treatment of neonatal HSV disease; The incidence of SAEs and AEs considered to be related to study treatment; The incidence of grade 3-4 AEs and SAEs, with or without relationship to study treatment; Intracellular pharmacokinetic parameters for the active diphosphate moiety of a Novel Antiviral Drug in peripheral blood mononuclear cells (PBMCs); Correlation of a Novel Antiviral Drug plasma and intracellular concentrations with qualitative and quantitative HSV detection in cerebrospinal fluid and blood by PCR |
|
| 15 |
Unknown †
|
Can ValAcyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
| Conditions: |
HIV Infections; Herpes Simplex |
| Interventions: |
Drug: ValAcyclovir; Drug: Placebo |
| Outcome Measures: |
Percentage activated CD8+ T-cells; Inflammatory markers; CD4 cell count; Virologic blips; Drug-related adverse events; HSV reactivations; Acyclovir-resistant HSV |
|
| 16 |
Recruiting
|
Can ValAcyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals With Herpes Simplex Virus Type 2?
| Conditions: |
HIV Infection; Herpesvirus 2, Human; HIV Infections |
| Interventions: |
Drug: valAcyclovir; Drug: Placebo |
| Outcome Measures: |
Time from baseline until reaching the primary endpoint, a composite of either a CD4 cell count ≤350 cells/mm3 measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, whichever occurs first.; Annual rate of change in CD4 count, calculated as the slope of patients' CD4 count change / time; Annual rate of change in the CD4 cell count percentage, calculated as the slope of the patient's CD4 count percentage change over time; Log10 plasma HIV viral load; Treatment-emergent adverse events and laboratory abnormalities; Frequency of episodes of HSV reactivations at any anatomic site; Proportion of microbiologically confirmed flares of HSV during the trial that are caused by laboratory-confirmed Acyclovir-resistant HSV; Quality of life |
|
| 17 |
Not yet recruiting
|
PACT for Individuals With Serious Mental Illness
| Condition: |
Schizophrenia and Disorders With Psychotic Feature |
| Intervention: |
Other: Patient Aligned Care Team (PACT) |
| Outcome Measures: |
Composite Prevention Score; Composite Diabetes Mellitus Score; medical and mental health treatment utilization and cost; Assess acceptability of the SMI-PACT model, and barriers and facilitators to its implementation; Investigate the relationships between organizational context, intervention factors, and patient and provider outcomes; Identify factors related to successful patient outcomes; VA Decision Support System National Database Extracts (DSS NDEs); Assessment of Chronic Illness Care (ACIC); patient Assessment of Chronic Illness Care (PACIC); Rogers' Adoption Questionnaire; Maslach Burnout Inventory (MBI); Behavior and Symptom Identification Scale - Revised (BASIS-R); Ambulatory Care Experiences Survey (ACES; Short Form); Interpersonal Support Evaluation List (ISEL); Medication Possession Ratio (MPR); Ethnographic field notes; Semi-structured qualitative interviews |
|
| 18 |
Recruiting
|
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
| Condition: |
Refractory Cold Agglutinin Disease |
| Intervention: |
Drug: Bortezomib |
| Outcome Measures: |
Number of patients who become transfusion-free after Bortezomib therapy.; Number of patients who have never been transfused with a >2g hemoglobin rise compared to baseline.; Number of CTC grade 3 and 4 adverse events.; Duration in months of transfusion independence.; Effect of treatment on the underlying clonal B cell disorder. |
|
| 19 |
Unknown †
|
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
| Condition: |
Multiple Myeloma |
| Intervention: |
Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib |
| Outcome Measure: |
response rate for induction chemotherapy |
|
| 20 |
Recruiting
|
HSV-tk + ValAcyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
| Condition: |
Prostatic Neoplasms |
| Intervention: |
Drug: HSV-tk +ValAcyclovir in Combination with Brachytherapy |
| Outcome Measures: |
1. Safety based on standard laboratory and clinical adverse event monitoring; Local control survival (measured by PSA and biopsy); Evaluate immunological markers |
|
